WT1基因在骨髓增殖性疾病中的表达及临床意义

Expression of WT1 gene in myeloproliferative disorders and its clinical significance

目的探讨WT1基因在骨髓增殖性疾病中的表达与临床意义。方法采用逆转录-聚合酶链反应方法检测30例骨髓增殖性疾病患者、10例正常人外周血的WT1基因表达。结果 10例正常人未检测到WT1基因的表达。30例骨髓增殖性疾病患者中有11例阳性(36.67%),根据血红蛋白及血小板值分期,Ⅰ期未测到WT1基因阳性表达,Ⅱ期阳性率36.36%,Ⅲ期阳性率63.64%,对WT1基因的相对量分析发现从Ⅰ～Ⅲ期WT1mRNA的表达水平逐渐增加,经统计学分析各期间均有差异。结论 RT-PCR检测WT1基因的表达可作为骨髓增殖性疾病的另外一个风险评估指标。

Objective To evaluate the expression of WT1 gene in myeloproliferative disorders and its clinical significance. Methods The expression of WT1 gene was measured in 30 pa- tients with myeloproliferative disorders and 10 normal controls by reverse transcriptase polymer- ase chain reaction（RT-PCR） method. Results WT1 gene was not found in 10 normal con- trols. The expression of WT1 gene increased in 11 of 30 patients with myeloproliferative disor- ders and the positive rate was 36.67%. According to the hemoglobin and platelet numerical staging, WT1 gene was＂ not found in these patients with myeloproliferative disorder who was in the first phase of stage. But the expression of WT1 gene was higher in these patients in second and third phases, the positive rates were 36.36% and 63.64% , respectively. The relative ex- pression level of WT1 gene increased from the first phase to the third phase. There was differ- ence between every two groups. Conclusion The expression of WT1 gene would be a addi- tional marker for risk assessment of myeloproliferative disorder.